CLINICAL TRIALS PROFILE FOR OSPEMIFENE

All Clinical Trials for Ospemifene

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00276094 ↗	A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women	Completed	Hormos Medical	Phase 3	2006-01-01	The purpose of this study is to determine whether ospemifene is more effective than placebo in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women.
NCT00276094 ↗	A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women	Completed	QuatRx Pharmaceuticals	Phase 3	2006-01-01	The purpose of this study is to determine whether ospemifene is more effective than placebo in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women.
NCT00276094 ↗	A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women	Completed	Shionogi	Phase 3	2006-01-01	The purpose of this study is to determine whether ospemifene is more effective than placebo in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women.
NCT00566982 ↗	A Clinical Study to Evaluate the Safety of Ospemifene	Completed	Hormos Medical	Phase 3	2007-10-01	The purpose of this study is to determine the efficacy and long-term safety of 60mg ospemifene in the treatment of VVA in postmenopausal women with intact uterus.
NCT00566982 ↗	A Clinical Study to Evaluate the Safety of Ospemifene	Completed	QuatRx Pharmaceuticals	Phase 3	2007-10-01	The purpose of this study is to determine the efficacy and long-term safety of 60mg ospemifene in the treatment of VVA in postmenopausal women with intact uterus.
NCT00566982 ↗	A Clinical Study to Evaluate the Safety of Ospemifene	Completed	Shionogi	Phase 3	2007-10-01	The purpose of this study is to determine the efficacy and long-term safety of 60mg ospemifene in the treatment of VVA in postmenopausal women with intact uterus.
NCT00630539 ↗	A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women	Completed	Hormos Medical	Phase 2	2007-08-01	The purpose of the study is to assess the efficacy, safety and tolerability of Ospemifene 5 mg, 15 mg, and 30 mg in the treatment of VVA in postmenopausal women to find the minimum effective dose below the lowest dose of 30 mg tested earlier in Phase II.

Clinical Trial Conditions for Ospemifene

Condition Name

Condition Name for Ospemifene
Intervention	Trials
Vaginal Diseases	6
Atrophy	6
Vaginal Dryness	1
Vulvovaginal Atrophy	1

Condition MeSH

Condition MeSH for Ospemifene
Intervention	Trials
Atrophy	7
Vaginal Diseases	6
Dyspareunia	1
Disease	1

Clinical Trial Locations for Ospemifene

Trials by Country

Trials by Country for Ospemifene
Location	Trials
United States	31
Spain	1

Trials by US State

Trials by US State for Ospemifene
Location	Trials
Georgia	2
California	2
Montana	1
Nebraska	1
Nevada	1

Clinical Trial Progress for Ospemifene

Clinical Trial Phase

Clinical Trial Phase for Ospemifene
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	6
Phase 2	1

Clinical Trial Status

Clinical Trial Status for Ospemifene
Clinical Trial Phase	Trials
Completed	8
Recruiting	1
Terminated	1

Clinical Trial Sponsors for Ospemifene

Sponsor Name

Sponsor Name for Ospemifene
Sponsor	Trials
Shionogi	7
QuatRx Pharmaceuticals	6
Hormos Medical	4

Sponsor Type

Sponsor Type for Ospemifene
Sponsor	Trials
Industry	17
Other	3